Martin Johansson

Chief Executive Officer at Glactone Pharma AB

Health Technology

Consumer Services

Profile

Martin Johansson is the founder of Glactone Pharma AB, which he founded in 2012 and where he holds the title of Chief Executive Officer.
He is currently an Associate Professor at the University of Lund.
Previously, he worked at Respiratorius AB from 2006 to 2011 as a Manager-Chemistry.

Martin Johansson active positions

Companies	Position	Start
University of Lund	Corporate Officer/Principal	-
Glactone Pharma AB Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden.	Chief Executive Officer	2011-12-31

All active positions of Martin Johansson

Former positions of Martin Johansson

Companies	Position	End
Respiratorius AB Respiratorius AB Pharmaceuticals: MajorHealth Technology Respiratorius AB engages in the development of drug candidates for Chronic Obstructive Pulmonary Disease, asthma, and cancer. The company was founded by Lars Christer Fedrik Fåhraeus and Staffan Skogwall in 1999 and is headquartered in Lund, Sweden.	Chief Tech/Sci/R&D Officer	-

See the detail of Martin Johansson's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Martin Johansson's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
	Health Technology

Private companies	1
Glactone Pharma AB Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden.	Health Technology